• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease
Zilebesiran met primary endpoint demonstrating greater than 15 mmHg reduction of systolic blood pressure at three months of treatment compared to placeboStudy met key secondary endpoints showing consistent and sustained reductions of systolic blood pressure at six monthsZilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertensionFull study results to be presented at an upcoming scientific conferenceBasel, 7 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced today that the Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi the...
Source: Roche Media News - September 7, 2023 Category: Pharmaceuticals Source Type: news

E-040 Natural history of vertebrobasilar dolichoectasia - multinational study
ConclusionThis study verifies malignancy of VBADA and encourage invasive treatment in early phase of disease progression based on radiological characteristics, age and sex of the patients when treatment option is seen suitable.Disclosures B. Rezai Jahromi: None. N. Ota: None. V. Srinivasan: None. S. Henriksson: None. R. Dashti: None. C. Schwartz: None. J. Jääskeläinen: None. A. Lindgren: None. T. Koivisto: None. B. Jahromi: None. K. Noda: None. M. Potts: None. R. Tanikawa: None. Y. Kalani: None. P. Vajkoczy: None. R. Spetzler: None. F. Göhre: None. J. Hernesniemi: None. M. Lawton: None. M. N...
Source: Journal of NeuroInterventional Surgery - July 30, 2023 Category: Neurosurgery Authors: Rezai Jahromi, B., Ota, N., Srinivasan, V., Henriksson, S., Dashti, R., Schwartz, C., Jääskeläinen, J., Lindgren, A., Koivisto, T., Jahromi, B., Noda, K., Potts, M., Tanikawa, R., Kalani, Y., Vajkoczy, P., Spetzler, R., Göh Tags: SNIS 20th annual meeting electronic poster abstracts Source Type: research

Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk
Partnership combines Roche ’s proven track record of successfully developing and launching innovative medicines worldwide withAlnylam ’s leadership in RNAi therapeuticsZilebesiran, a Phase 2 RNAi therapeutic, has best-in-disease potential for patients with hypertension at high risk of cardiovascular morbidity and mortality, by robustly and durably lowering blood pressureHypertension, the leading cause of cardiovascular disease, affects more than 1.2 billion adults worldwide. While several therapies exist, a significant unmet need, especially for high risk patients, remains.1Basel, 24 July 2023 - Roche (SIX: RO, ROG; OT...
Source: Roche Media News - July 24, 2023 Category: Pharmaceuticals Source Type: news

Risk and population attributable fraction of stroke subtypes in Japan
CONCLUSION: Although there are differences according to the subtypes, hypertension could be regarded as the most crucial target for preventing strokes in Japan.PMID:37460296 | DOI:10.2188/jea.JE20220364
Source: Journal of Epidemiology - July 17, 2023 Category: Epidemiology Authors: Hiroshi Yatsuya Kazumasa Yamagishi Yuanying Li Isao Saito Yoshihiro Kokubo Isao Muraki Manami Inoue Shoichiro Tsugane Hiroyasu Iso Norie Sawada Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17